. 2022 Aug 30;22:358. doi: 10.1186/s12905-022-01939-z

Table 2.

Univariate analyses for prediction of residual lesion in subsequent hysterectomy specimen

Parameter	Numbers		OR (95%CI)	P-values
Parameter	Total	Residual lesion (%)	OR (95%CI)	P-values
Age
≥ 50	254	42 (16.5%)	1.355 (0.886–2.072)	0.160
< 50	486	62 (12.8%)	1.355 (0.886–2.072)	0.160
Menopause
Yes	201	35 (17.4%)	1.436 (0.922–2.238)	0.108
No	539	69 (12.8%)	1.436 (0.922–2.238)	0.108
Smoking
Yes	13	3 (23.1%)	1.959 (0.503–6.872)	0.409
No	727	101 (13.9%)	1.959 (0.503–6.872)	0.409
Diseases of the immune system
Yes	64	9 (14.1%)	1.001 (0.479–2.092)	0.998
No	676	95 (14.1%)	1.001 (0.479–2.092)	0.998
Gravidity
≥ 3	506	67 (13.2%)	0.813 (0.526–1.256)	0.349
< 3	234	37 (15.8%)	0.813 (0.526–1.256)	0.349
Parity
≥ 2	312	45 (14.4%)	1.054 (0.694–1.602)	0.805
< 2	428	59 (13.8%)	1.054 (0.694–1.602)	0.805
Lesion range
≥ 3	409	69 (16.9%)	1.716 (1.110–2.653)	0.014*
< 3	331	35 (10.6%)	1.716 (1.110–2.653)	0.014*
Cone margin status
Positive	254	70 (27.6%)	5.058 (3.244–7.885)	< 0.001*
Negative	486	34 (7%)	5.058 (3.244–7.885)	< 0.001*
Glandular involvement
Positive	568	98 (17.3%)	5.769 (2.483–13.404)	< 0.001*
Negative	172	6 (3.5%)	5.769 (2.483–13.404)	< 0.001*
HPV-16/18 infection
Positive	408	79 (19.4%)	2.949 (1.832–4.746)	< 0.001*
Negative	332	25 (7.5%)	2.949 (1.832–4.746)	< 0.001*
Multiple HR-HPV infection
Positive	191	38 (19.9%)	1.818 (1.172–2.818)	0.007*
Negative	549	66 (12%)	1.818 (1.172–2.818)	0.007*
Lesion level
CIN II	58	6 (10.3%)	0.688 (0.288–1.644)	0.397
CIN III	682	98 (14.4%)	0.688 (0.288–1.644)	0.397

HR-HPV high-risk human papillomavirus, OR odds ratio, CI confidence interval, CIN cervical intraepithelial neoplasia,

*Statistically significant